Barbara Burtness MD
Anthony N. Brady Professor of Medicine; Chief Translational Research Officer; Associate Director, Translational Science; Chief, Head and Neck Cancers/Sarcoma; Co-Leader, Developmental Therapeutics Program; Director, Yale Head and Neck SPORE, Yale Cancer Center, Yale School of Medicine, New Haven, ConnecticutDr. Barbara Burtness is Anthony N. Brady Professor of Medicine at the Yale University School of Medicine. She is founding director of the Yale Head and Neck SPORE, co-leader of the Developmental Therapeutics Program, and director of the Head and Neck Clinical Research Program at Yale Cancer Center.
Dr. Burtness’s research focuses on clinical trials of immunotherapy and translational studies of resistance to immunotherapy and EGFR inhibition, and synthetic lethal approaches for HPV-negative head and neck cancer. She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multicenter trials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers, and she co-leads the Stand Up to Cancer Head and Neck Cancer Team.
Dr. Burtness co-edits the text Molecular Determinants of Head and Neck Cancer. Her research has been published in numerous peer-reviewed journals, including The Lancet, Journal of Clinical Oncology, The Lancet Oncology, and Clinical Cancer Research.
Disclosures
- Honoraria/Consulting/Data Safety Monitoring Boards: AbbVie, ALX Oncology, Astra Zeneca, Coherus, Cue Biopharma, Eisai, Glaxo Smith Kline, IMS Consulting, IO Biotech, Kura, Merck KgaA, Merck, Merus, Orphagen, Vaccinex, Slingshot Bio, Surface
Recent Contributions to PracticeUpdate:
- ASCO 2024: Abstract Recommendations From Dr. Barbara Burtness for Head and Neck Cancer
- Reduced-Volume Irradiation of the Uninvolved Neck in Patients With Nasopharyngeal Cancer
- 2023 Top Story in Oncology: PD-1 Inhibition for Nasopharyngeal Cancer
- ESMO 2023: Recommendations From Dr. Barbara Burtness for Head and Neck Cancer
- Immunochemotherapy as a Single Treatment for Larynx Preservation
- Durvalumab Added to First-Line Carboplatin/Paclitaxel for Recurrent/Metastatic HNSCC
- Adjuvant Chemotherapy for Nasopharynx Cancer
- Final OS Analysis of JUPITER-2: Incorporation of ICI in the First Line for Recurrent/Metastatic Nasopharyngeal Cancer
- PD-1 Blockade Plus Induction Chemotherapy and Concurrent Chemoradiation for Locally Advanced Nasopharynx Cancer
- 2022 Top Story in Oncology: Nivolumab/Ipilimumab in First-Line for Recurrent/Metastatic HNSCC—CheckMate 651